Is NAIL a Good ETF to Buy?
If you’re thinking about buying the NAIL ETF, this article…
Sell
44
OPT Quote, Financials, Valuation and Earnings
Last price:
$3.89
Seasonality move
:
-4.47%
Day range:
$3.67 - $3.81
52-week range:
$1.79 - $5.45
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2,361.28x
P/B ratio:
--
Volume:
20.6K
Avg. volume:
12.4K
1-year change:
18.49%
Market cap:
$567.8M
Revenue:
$124.7K
EPS (TTM):
-$2.76
Analysts' Opinion
-
Consensus RatingOpthea has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $11.80, Opthea has an estimated upside of 229.72% from its current price of $3.69.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $8.00 representing 100% downside risk from its current price of $3.69.
Fair Value
-
According to the consensus of 4 analysts, Opthea has 229.72% upside to fair value with a price target of $11.80 per share.
OPT vs. S&P 500
-
Over the past 5 trading days, Opthea has underperformed the S&P 500 by -7.11% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Opthea does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Opthea has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Opthea reported revenues of --.
Earnings Growth
-
Opthea has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Opthea reported earnings per share of --.
Enterprise value:
536.9M
EV / Invested capital:
--
Price / LTM sales:
2,361.28x
EV / EBIT:
--
EV / Revenue:
4,306.91x
PEG ratio (5yr expected):
-0.04x
EV / Free cash flow:
--
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-145.56%
Net Income Margin (TTM):
-176665.74%
Return On Equity:
--
Return On Invested Capital:
-669.85%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2017-06-30 | 2018-06-30 | 2019-06-30 | 2018-06-30 | 2019-06-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$7.5M | -$21.9M | -$26.2M | -- | -- | |
| EBITDA | -$7.5M | -$21.9M | -$26.2M | -- | -- | |
| Diluted EPS | -$0.21 | -$0.43 | -$0.45 | -- | -- | |
| Period Ending | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $49M | $138.1M | $59.9M | $98.4M | $188.2M | |
| Total Assets | $49.4M | $138.4M | $60M | $98.6M | $188.8M | |
| Current Liabilities | $4.8M | $3.1M | $12M | $18.7M | $64.1M | |
| Total Liabilities | $4.9M | $3.1M | $12.1M | $104.5M | $264.6M | |
| Total Equity | $44.6M | $135.3M | $48M | -$5.9M | -$75.8M | |
| Total Debt | -- | -- | -- | $85.7M | $141.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -- | -- | |
| Cash From Investing | -- | -- | -- | -- | -$11K | |
| Cash From Financing | -- | -- | -- | -- | $34.8M | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
OPT
Sector
Market Cap
$567.8M
$48.9M
Price % of 52-Week High
67.71%
49.34%
Dividend Yield
0%
0%
Shareholder Yield
-78.23%
-0.74%
1-Year Price Total Return
18.49%
-30.56%
Beta (5-Year)
0.710
0.754
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$3.76
200-day SMA
Buy
Level
$3.27
Bollinger Bands (100)
Sell
Level
3.02 - 4.36
Chaikin Money Flow
Sell
Level
-4.8M
20-day SMA
Buy
Level
$3.55
Relative Strength Index (RSI14)
Buy
Level
52.15
ADX Line
Buy
Level
31.51
Williams %R
Neutral
Level
-36.3764
50-day SMA
Sell
Level
$3.70
MACD (12, 26)
Buy
Level
0.04
25-day Aroon Oscillator
Buy
Level
44
On Balance Volume
Neutral
Level
3.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-6.3974)
Sell
CA Score
(Annual)
Level (-10.3201)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (10.9036)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.
Stock Forecast FAQ
In the current month, OPT has received 4 Buy ratings 0 Hold ratings, and 0 Sell ratings. The OPT average analyst price target in the past 3 months is $11.80.
-
Where Will Opthea Stock Be In 1 Year?
According to analysts, the consensus estimate is that Opthea share price will rise to $11.80 per share over the next 12 months.
-
What Do Analysts Say About Opthea?
Analysts are divided on their view about Opthea share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Opthea is a Sell and believe this share price will drop from its current level to $8.00.
-
What Is Opthea's Price Target?
The price target for Opthea over the next 1-year time period is forecast to be $11.80 according to 4 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is OPT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Opthea is a Buy. 4 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of OPT?
You can purchase shares of Opthea via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Opthea shares.
-
What Is The Opthea Share Price Today?
Opthea was last trading at $3.89 per share. This represents the most recent stock quote for Opthea. Yesterday, Opthea closed at $3.69 per share.
-
How To Buy Opthea Stock Online?
In order to purchase Opthea stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
3 High Dividend Dow Jones Stocks
Thanks to surging stock prices over the past two years,…
Will American Tower Stock Recover?
The performance of the real estate investment trust, or REIT,…
Stock Ideas
Sell
42
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 125x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
50
NARI alert for Jan 7
Inari Medical [NARI] is up 22.25% over the past day.
Buy
70
PDEX alert for Jan 7
Pro-Dex [PDEX] is down 10.89% over the past day.
Buy
52
ALCO alert for Jan 7
Alico [ALCO] is down 3.89% over the past day.
